Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bayer Says India's Natco Has No Ground For Compulsory License; Blames Lack of Drug Availability On Poor Health Infrastructure

This article was originally published in The Pink Sheet Daily

Executive Summary

The German polymers-to-pharmaceuticals conglomerate has said that "extensive use of compulsory licenses will in the long-term undermine and threaten the patent system."

You may also be interested in...



Thailand's Cost Control Measures And What They Mean For Pharma - IMS Analysis

SHANGHAI - Thailand's recent clampdown on public healthcare spending means multinational drug makers will have to look for news ways to tap the country's drug market, according to IMS Health

ViiV Healthcare Questions Natco's Ability To Make And Sell Selzentry In India; Stays Silent On Voluntary License Issue

MUMBAI - ViiV Healthcare - formed by GlaxoSmithKline Pharmaceuticals Plc and Pfizer Inc. in 2009 to work on a range of HIV/AIDS medications - struck back with a volley of questions to Natco Pharma Ltd., which had sought a voluntary license in December 2010 to manufacture generic versions of Selzentry

Cipla Targets Merck's Leading Anti-HIV Brand Isentress; Applies For Voluntary License In India

MUMBAI - Merck & Co.'s HIV integrase inhibitor Isentress (raltegravir) may have been a big success across many markets, but in India the anti-AIDS drug may be short of its mark. Leading home-grown company Cipla Ltd. has taken the route of applying for a "voluntary license" for the drug to New Jersey-headquartered Merck because Cipla says it is not reaching needy patients in India and it is priced exorbitantly

Related Content

Topics

UsernamePublicRestriction

Register

PS072628

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel